Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lanifibranor versus placebo in adults with non-cirrhotic NASH and F2/F3 fibrosis
2023-508248-23-00Phase 3Authorised
- Sponsor
- Inventiva
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Lanifibranor with Placebo (2 arms). Primary endpoint: Resolution of NASH and improvement of fibrosis at Week 72. Planned start Nov 2021; status: authorised.
02
Drugs
lanifibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2023-508248-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508248-23-00.